Medical Xpress
New weight loss pill gets approval, but FDA seeks more safety data
Eli Lilly's new obesity drug Foundayo has received FDA approval, but the agency is requiring the pharmaceutical giant to conduct further studies on potential heart and liver risks. The conditional green light reflects ongoing regulatory caution as blockbuster weight loss drugs face intensifying scrutiny over long-term safety profiles. For patients and investors alike, the approval marks a milestone — though key questions about the drug's risk picture remain unanswered.
Read article →Guardian Health
Utah reports more than 600 measles cases as outbreak spreads across US
Utah has surpassed 600 measles cases in an ongoing outbreak, with state health officials reporting 85% of those infected were unvaccinated. The surge has resulted in dozens of hospitalizations, cementing Utah as one of the hardest-hit states in a broader national resurgence of the disease. The outbreak underscores the direct consequences of declining vaccination rates on public health infrastructure.
Read article →Medical Xpress
A two-way brain interface could help restore walking after paralysis by linking thoughts, robotic legs and sensation
A team of researchers from USC, UC Irvine, and Caltech is developing a fully implantable brain-computer interface that allows paralyzed patients to control robotic exoskeletons using thought alone. What sets the system apart is its two-way design: it not only translates neural signals into movement commands but also feeds sensory feedback back to the brain. The advance could mark a significant step toward restoring both mobility and physical sensation in patients with paraplegia.
Read article →Medical Xpress
Study finds widening racial and gender inequities in polysubstance overdose deaths
Overdose deaths linked to polysubstance use, particularly the combination of opioids and stimulants, have surged across the U.S., with the burden falling hardest on non-Hispanic Black and Hispanic men. The trend signals a dangerous evolution in the overdose crisis that existing public health responses have largely failed to address equitably. Targeted interventions for these communities are increasingly urgent as the gap widens.
Read article →Medical Xpress
A new depression treatment may rival electroconvulsive therapy while avoiding one of its biggest drawbacks
Magnetic seizure therapy matched the effectiveness of electroconvulsive therapy in treating severe, treatment-resistant depression while causing significantly fewer cognitive side effects, according to a major international trial published in *The Lancet Psychiatry*. ECT, long considered the gold standard for hard-to-treat depression, has been held back by memory loss and other cognitive impairments that deter many patients from pursuing it. MST's comparable efficacy without that trade-off could mark a turning point in how the condition is treated.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →